| Frank Ammaturo, MD | |
|
1203 Langhorne Newtown Rd Ste 320, Langhorne, PA 19047-1235 | |
| (215) 750-7818 | |
| (215) 752-0436 |
| Full Name | Frank Ammaturo |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 27 Years |
| Location | 1203 Langhorne Newtown Rd Ste 320, Langhorne, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720055296 | NPI | - | NPPES |
| 0702774 | Other | PA | CIGNA PA |
| P01123858 | Other | PA | RAILROAD MEDICARE |
| 1008513740005 | Medicaid | PA | |
| 30120524 | Other | PA | KEYSTONE FIRST |
| 1535791 | Other | PA | PENNSYLVANIA BLUE SHIELD |
| 2220636000 | Other | PA | KEYSTONE |
| 7850434 | Other | PA | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD070113L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary Medical Center | Langhorne, PA | Hospital |
| Rothman Orthopaedic Specialty Hospital | Bensalem, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trinity Health Mid-atlantic Medical Group | 7416861885 | 239 |
News Archive
SXC Health Solutions Corp., a leading provider of technology and pharmacy benefit management services, announces that it has been awarded a three-year Health Care Information Technology service contract from Health Alliance Plan of Michigan, a health plan with an annual health spend of approximately $250 million. Health Alliance Plan markets health plan products in the commercial and Medicare Part D market segments.
Patterns of brain responses to rewards are a significant predictor of pain symptoms—a link that is already present by adolescence—and may be influenced by gene variants affecting pain sensitivity, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
UnitedHealth is the second major company to announce its exit in advance of the changes that will take effect as a result of the health law. Meanwhile, Blues plans in Iowa and South Dakota announced plans to skip participation in those two states' health exchanges in 2014.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.
› Verified 2 days ago
| Entity Name | Trinity Health Mid-atlantic Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093771271 PECOS PAC ID: 7416861885 Enrollment ID: O20040326000613 |
News Archive
SXC Health Solutions Corp., a leading provider of technology and pharmacy benefit management services, announces that it has been awarded a three-year Health Care Information Technology service contract from Health Alliance Plan of Michigan, a health plan with an annual health spend of approximately $250 million. Health Alliance Plan markets health plan products in the commercial and Medicare Part D market segments.
Patterns of brain responses to rewards are a significant predictor of pain symptoms—a link that is already present by adolescence—and may be influenced by gene variants affecting pain sensitivity, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
UnitedHealth is the second major company to announce its exit in advance of the changes that will take effect as a result of the health law. Meanwhile, Blues plans in Iowa and South Dakota announced plans to skip participation in those two states' health exchanges in 2014.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Frank Ammaturo, MD 41 University Dr, Suite 300, Newtown, PA 18940-1873 Ph: (215) 710-7037 | Frank Ammaturo, MD 1203 Langhorne Newtown Rd Ste 320, Langhorne, PA 19047-1235 Ph: (215) 750-7818 |
News Archive
SXC Health Solutions Corp., a leading provider of technology and pharmacy benefit management services, announces that it has been awarded a three-year Health Care Information Technology service contract from Health Alliance Plan of Michigan, a health plan with an annual health spend of approximately $250 million. Health Alliance Plan markets health plan products in the commercial and Medicare Part D market segments.
Patterns of brain responses to rewards are a significant predictor of pain symptoms—a link that is already present by adolescence—and may be influenced by gene variants affecting pain sensitivity, reports a study in PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.
UnitedHealth is the second major company to announce its exit in advance of the changes that will take effect as a result of the health law. Meanwhile, Blues plans in Iowa and South Dakota announced plans to skip participation in those two states' health exchanges in 2014.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.
› Verified 2 days ago
Vincent Michael Figueredo, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1203 Langhorne Newtown Rd Ste 320, Langhorne, PA 19047 Phone: 215-750-7818 Fax: 215-752-0436 | |
Dr. Gregory P Zollner, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 240 Middletown Blvd, Ste 200, Langhorne, PA 19047 Phone: 215-757-5772 Fax: 215-757-5494 | |
Dr. John A Volpe, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1203 Langhorne Newtown Rd Ste 234, Langhorne, PA 19047 Phone: 215-750-2911 Fax: 215-750-2917 | |
Ellen Miller, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 825 Town Center Dr, Suite 152, Langhorne, PA 19047 Phone: 215-741-3510 Fax: 215-741-3519 | |
Jonathan Gold, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1203 Langhorne Newtown Rd, Suite 320, Langhorne, PA 19047 Phone: 215-750-7818 Fax: 215-752-0436 | |
Ronald H Fields, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1203 Langhorne Newtown Rd, Suite 320, Langhorne, PA 19047 Phone: 215-750-7818 Fax: 215-752-0436 | |
Fozia Farooqui, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1203 Langhorne Newtown Rd Ste 226, Langhorne, PA 19047 Phone: 215-710-4460 Fax: 215-710-4465 |